Talks

Reducing cardiorenal risk with glucose-lowering agents in type 2 diabetes

Reducing cardiovascular risk in type 2 diabetes by glucose lowering – does the drug matter?
2023 – Lale Tokgozoglu
Understanding protective effects in diabetic kidney disease: from biomarkers to clinical outcomes
2023 – Robert Eckel
Emerging glucose-lowering therapies in type 2 diabetes: insights from the trials
2023 – Abhinav Sharma